Pierce G F, Lusher J M, Brownstein A P, Goldsmith J C, Kessler C M
Department of Pathology, Washington University Medical Center, St Louis, Mo.
JAMA. 1989 Jun 16;261(23):3434-8.
Treatment of hemophilia, although greatly improved in recent years, continues to be problematic owing to infectious complications of blood product replacement therapy. This report examines the therapeutic options presently available for the treatment of hemophilia, focusing on the potential for repeated viral exposure to influence the progression of infectious disease, decreased risks of viral transmission with blood products produced using newer viral inactivation procedures, higher economic costs of newer blood products, and the current inadequate supply of blood products in the United States.
血友病的治疗尽管近年来有了很大改善，但由于血液制品替代疗法的感染性并发症，仍然存在问题。本报告探讨了目前可用于治疗血友病的各种疗法，重点关注反复接触病毒对传染病进展的潜在影响、采用新型病毒灭活程序生产的血液制品降低病毒传播风险的情况、新型血液制品的较高经济成本以及美国目前血液制品供应不足的问题。
